浏览全部资源
扫码关注微信
甲状旁腺激素类似物与双膦酸盐序贯治疗骨质疏松症有效性与安全性的Meta分析
Effectiveness and safety of sequential therapy with parathyroid hormone analogues and bisphosphonates for osteoporosis： a meta-analysis
- 中国药房 2024年35卷第24期 页码：3059-3064
- 作者机构：
1.甘肃中医药大学第一临床医学院，兰州 730000
2.甘肃省人民医院内分泌科，兰州 730000
3.甘肃代谢性疾病临床研究中心，兰州 730000
4.江苏大学医学院，江苏 镇江 212000
- 作者简介：
硕士研究生。研究方向：内分泌与代谢性疾病（骨质疏松症）的诊治。E-mail：463435@163.com
主任医师，教授，博士生导师，博士。研究方向：内分泌与代谢性疾病（骨质疏松症）的诊治。E-mail：tlm7066@sina.com
- 基金信息：甘肃省卫生健康行业科研计划项目(GSWSK-Y2020-08);兰州市人才创新创业项目(2018-RC-79)
DOI：10.6039/j.issn.1001-0408.2024.24.16
中图分类号： R979.9;R681纸质出版日期：2024-12-30，
收稿日期：2024-06-23，
修回日期：2024-10-04，
- 稿件说明：
移动端阅览
姚娟娟,石春霞,张乐媛等.甲状旁腺激素类似物与双膦酸盐序贯治疗骨质疏松症有效性与安全性的Meta分析 Δ[J].中国药房,2024,35(24):3059-3064.
YAO Juanjuan,SHI Chunxia,ZHANG Leyuan,et al.Effectiveness and safety of sequential therapy with parathyroid hormone analogues and bisphosphonates for osteoporosis： a meta-analysis[J].ZHONGGUO YAOFANG,2024,35(24):3059-3064.
姚娟娟,石春霞,张乐媛等.甲状旁腺激素类似物与双膦酸盐序贯治疗骨质疏松症有效性与安全性的Meta分析 Δ[J].中国药房,2024,35(24):3059-3064. DOI： 10.6039/j.issn.1001-0408.2024.24.16.
YAO Juanjuan,SHI Chunxia,ZHANG Leyuan,et al.Effectiveness and safety of sequential therapy with parathyroid hormone analogues and bisphosphonates for osteoporosis： a meta-analysis[J].ZHONGGUO YAOFANG,2024,35(24):3059-3064. DOI： 10.6039/j.issn.1001-0408.2024.24.16.
摘要
目的
2
评价甲状旁腺激素类似物和双膦酸盐序贯治疗对骨质疏松症的有效性和安全性。
方法
2
检索PubMed、Embase、the Cochrane Library、Web of Science、中国知网、维普网、万方数据、中国生物医学文献服务系统等中英文数据库，检索时间自建库至2024年3月25日。由2名研究员各自进行文献检索、筛选、数据提取。采用Review Manager 5.4软件进行Meta分析。针对可能的异质性来源根据试验组不同给药顺序进行亚组分析及敏感性分析。
结果
2
共纳入7项随机对照试验，包含2 461例受试者，其中试验组1 215例，对照组1 246例。Meta分析结果显示，试验组采用甲状旁腺激素类似物与双膦酸盐序贯治疗对腰椎[SMD＝0.90，95%CI（0.44，1.35），
P
＜0.001
]
、全髋关节[SMD＝0.68，95%CI（0.14，1.21），
P
＝0.01
]
、股骨颈[SMD＝0.45，95%CI（0.04，0.86），
P
＝0.03
]
骨密度的改善效果均显著优于对照组，在降低治疗后骨折发生率方面显著优于对照组[OR＝0.72，95%CI（0.54，0.97），
P
＝0.03
]
，两组患者不良反应发生率比较差异无统计学意义[OR＝1.21，95%CI（0.99，1.46），
P
＝0.06
]
。根据试验组给药顺序进行亚组分析，结果显示，双膦酸盐转换为甲状旁腺激素类似物组[SMD＝0.56，95%CI（0.09，1.03），
P
＝0.02
]
或甲状旁腺激素类似物转换为双膦酸盐组[SMD＝0.97，95%CI（0.49，1.46），
P
＜0.001
]
腰椎骨密度改善效果均显著优于对照组，双膦酸盐转换为甲状旁腺激素类似物组全髋关节骨密度改善效果显著优于对照组[SMD＝0.66，95%CI（0.18，1.13），
P
＝0.007
]
。敏感性分析提示本研究结果稳健。
结论
2
甲状旁腺激素类似物与双膦酸盐序贯治疗可被推荐为骨质疏松症患者的有效治疗方法，安全性良好，且序贯给药顺序应当根据患者的具体情况和骨骼部位的不同反应进行个性化调整。
Abstract
OBJECTIVE
2
To evaluate the effectiveness and safety of sequential therapy with parathyroid hormone analogues and bisphosphonates for osteoporosis.
METHODS
2
PubMed， Embase， the Cochrane Library， Web of Science， China National Knowledge Infrastructure， VIP， Wanfang data， and SinoMed were searched in both English and Chinese databases from their inception to March 25， 2024. Two researchers independently conducted literature searches， screening， and data extraction. Review Manager 5.4 software was used for the meta-analysis. Subgroup analyses and sensitivity analyses were performed based on different medication sequences in the treatment group to account for potential sources of heterogeneity.
RESULTS
2
A total of 7 randomized controlled trials involving 2 461 participants were included， with 1 215 in the treatment group and 1 246 in the control group. The meta-analysis results showed that the treatment group using sequential therapy with parathyroid hormone analogues and bisphosphonates had superior effects on improving bone mineral density at the lumbar spine [SMD＝0.90， 95%CI （0.44， 1.35），
P
＜0.001
]
， total hip [SMD=0.68， 95%CI （0.14， 1.21），
P
＝0.01
]
， and femoral neck [SMD＝0.45， 95%CI （0.04， 0.86），
P
＝0.03
]
compared to the control group. It also significantly outperformed the control group in reducing the incidence of fractures post-treatment [OR＝0.72， 95%CI （0.54， 0.97），
P
＝0.03
]
. No significant difference was noted in the incidence of adverse reactions between the two groups [OR＝1.21， 95%CI （0.99， 1.46），
P
＝0.06
]
. Subgroup analysis based on intervention measures in the treatment group showed that switching from bisphosphonates to parathyroid hormone analogues [SMD＝0.56， 95%CI （0.09， 1.03），
P
＝0.02
]
or switching from parathyroid hormone analogues to bispho
sphonates [SMD＝0.97， 95%CI （0.49， 1.46），
P
＜0.001
]
both significantly potentiated lumbar spine bone mineral density compared to the control group. Switching from bisphosphonates to parathyroid hormone analogues also significantly promoted total hip bone mineral density compared to the control group [SMD＝0.66， 95%CI
（0.18， 1.13），
P
＝0.007
]
. Sensitivity analysis indicated that the results of this study were robust.
CONCLUSIONS
2
Sequential therapy with parathyroid hormone analogues and bisphosphonates can be recommended as an effective treatment for patients with osteoporosis， with good safety profiles. The medication sequences should be individually adjusted based on the patient’s particular situation and the different responses of various skeletal sites.
关键词
甲状旁腺激素类似物双膦酸盐序贯治疗骨质疏松症骨密度
Keywords
diphosphonatessequential therapyosteoporosisbone mineral density
references
VAN DER BURGH A C，DE KEYSER C E，ZILLIKENS M C，et al. The effects of osteoporotic and non-osteoporotic medications on fracture risk and bone mine-ral density[J]. Drugs，2021，81（16）：1831-1858.
QASEEM A，HICKS L A，ETXEANDIA-IKOBALTZETA I，et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults：a living clinical guideline from the American College of Physicians[J]. Ann Intern Med，2023，176（2）：224-238.
US Preventive Services Task Force，CURRY S J，KRIST A H，et al. Screening for osteoporosis to prevent fractures：US Preventive Services Task Force recommendation statement[J]. JAMA，2018，319（24）：2521-2531.
DEARDORFF W J，CENZER I，NGUYEN B，et al. Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis：a meta-analysis of randomized clinical trials[J]. JAMA Intern Med，2022，182（1）：33-41.
CHENG C，WENTWORTH K，SHOBACK D M. New frontiers in osteoporosis therapy[J]. Annu Rev Med，2020，71：277-288.
LANGDAHL B L，LIBANATI C，CRITTENDEN D B， et al. Romosozumab （sclerostin monoclonal antibody） versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy：a randomised，open-label，phase 3 trial[J]. Lancet，2017，390（10102）：1585-1594.
SAUL D，DRAKE M T. Update on approved osteoporosis therapies including combination and sequential use of agents[J]. Endocrinol Metab Clin North Am，2021，50（2）：179-191.
RASHKI KEMMAK A，REZAPOUR A，JAHANGIRI R，et al. Economic burden of osteoporosis in the world：a systematic review[J]. Med J Islam Repub Iran，2020，34：154.
FINKELSTEIN J S，HAYES A，HUNZELMAN J L，et al. The effects of parathyroid hormone，alendronate，or both in men with osteoporosis[J]. N Engl J Med，2003，349（13）：1216-1226.
COSMAN F，ERIKSEN E F，RECKNOR C，et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide[rhPTH（1-34）] in postmenopausal osteoporosis[J]. J Bone Miner Res，2011，26（3）：503-511.
YANG D Z，TAN J，LONG Y F，et al. Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis：a prospective study[J]. Aging Clin Exp Res，2023，35（3）：531-539.
中华医学会骨质疏松症和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南：2022[J]. 中华骨质疏松症和骨矿盐疾病杂志，2022，15（6）：573-611.
Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for diagnosis and treatment of primary osteoporosis：2022[J]. Chin J Osteoporos Bone Miner Res，2022，15（6）：573-611.
ACOG Committee on Clinical Practice Guidelines-gynecology. Management of postmenopausal osteoporosis：ACOG clinical practice guideline No. 2[J]. Obstet Gynecol，2022，139（4）：698-717.
BLACK D M，BILEZIKIAN J P，ENSRUD K E，et al. One year of alendronate after one year of parathyroid hormone （1-84） for osteoporosis[J]. N Engl J Med，2005，353（6）：555-565.
COSMAN F，MILLER P D，WILLIAMS G C，et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis：results of the ACTIVExtend trial[J]. Mayo Clin Proc，2017，92（2）：200-210.
GREENSPAN S L，FITZPATRICK L A，MITLAK B， et al. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis：post hoc analysis of ACTIVExtend[J]. Menopause，2020，27（10）：1137-1142.
HAGINO H，SUGIMOTO T，TANAKA S，et al. A randomized，controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture：primary results of the Japanese osteoporosis intervention trial-05[J]. Osteoporos Int，2021，32（11）：2301-2311.
NANKI T，KAWAZOE M，UNO K，et al. Improvement in glucocorticoid-induced osteoporosis on switching from bisphosphonates to once-weekly teriparatide：a rando-mized open-label trial[J]. J Clin Med，2022，12（1）：292.
RITTMASTER R S，BOLOGNESE M，ETTINGER M P，et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate[J]. J Clin Endocrinol Metab，2000，85（6）：2129-2134.
包呼和，孙官文，王剑，等. 特立帕肽和双膦酸盐序贯治疗高龄骨质疏松症患者的疗效观察[J]. 实用临床医药杂志，2021，25（16）：95-98.
BAO H H，SUN G W，WANG J，et al. Efficacy observation on sequential therapy with teriparatide and bispho-sphonates for senile patients with osteoporosis[J]. J Clin Med Pract，2021，25（16）：95-98.
LOU S H，LV H C，WANG G Q，et al. The effect of sequential therapy for postmenopausal women with osteoporosis：a PRISMA-compliant meta-analysis of randomized controlled trials[J]. Medicine，2016，95（49）：e5496.
LEDER B Z. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy[J]. JBMR Plus，2018，2（2）：62-68.
ERIKSEN E F，BROWN J P. Commentary：concurrent administration of PTH and antiresorptives：additive effects or DXA cosmetics[J]. Bone，2016，86：139-142.
WHITMARSH T，TREECE G M，GEE A H，et al. Mapping bone changes at the proximal femoral cortex of postmenopausal women in response to alendronate and teriparatide alone，combined or sequentially[J]. J Bone Miner Res，2015，30（7）：1309-1318.
FINKELSTEIN J S，WYLAND J J，LEE H，et al. Effects of teriparatide，alendronate，or both in women with postmenopausal osteoporosis[J]. J Clin Endocrinol Metab，2010，95（4）：1838-1845.
0
浏览量
1
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 邮编：400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies